Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Venugopal, Gudipati"'
Autor:
Michael W. Moles, Henry Erdlei, Lutz Menzel, Marialucia Massaro, Agnese Fiori, Mario Bunse, Moritz Schrimpf, Kerstin Gerlach, Venugopal Gudipati, John Reiser, Ketan Mathavan, Jodie P. Goodrich, Johannes B. Huppa, Jan Krönke, Bahram Valamehr, Uta E. Höpken, Armin Rehm
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Multiple myeloma (MM) is a plasma cell disease with a preferential bone marrow (BM) tropism. Enforced expression of tissue-specific chemokine receptors has been shown to successfully guide adoptively-transferred CAR NK cells towards the malignant mil
Externí odkaz:
https://doaj.org/article/2dd8f8910e9849f68e43bc637bdeee21
Autor:
Torsten Tonn, Hans Klingemann, Winfried S Wels, Jiri Eitler, Natalie Wotschel, Laurent Boissel, Michael Bachmann, Wiebke Rackwitz, Venugopal Gudipati, Nivedha Murali Shankar, Anastasia Sidorenkova, Johannes B Huppa, Paola Ortiz-Montero, Corinna Opitz, Stephan R Künzel, Susanne Michen, Achim Temme, Liliana Rodrigues Loureiro, Anja Feldmann
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background The antitumor activity of natural killer (NK) cells can be enhanced by specific targeting with therapeutic antibodies that trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or by genetic engineering to express chimeric antigen r
Externí odkaz:
https://doaj.org/article/635e8a9c7ed146e6934cedabb216012a
Autor:
Torsten Tonn, Winfried Wels, Hans Klingemann, Jiri Eitler, Natalie Wotschel, Laurent Boissel, Paola Ortiz Montero, Wiebke Rackwitz, Venugopal Gudipati, Johannes Huppa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/6631a9096b6341f49cfecf75a7de5933
Autor:
Erika Garner-Spitzer, Angelika Wagner, Venugopal Gudipati, Anna-Margarita Schoetta, Maria Orola-Taus, Michael Kundi, Renate Kunert, Patrick Mayrhofer, Johannes B. Huppa, Hannes Stockinger, Rita Carsetti, Pia Gattinger, Rudolf Valenta, Bernhard Kratzer, Al Nasar Ahmed Sehgal, Winfried F. Pickl, Walter Reinisch, Gottfried Novacek, Ursula Wiedermann
Publikováno v:
EBioMedicine, Vol 96, Iss , Pp 104788- (2023)
Summary: Background: Patients with inflammatory bowel disease (IBD) and healthy controls received primary SARS-CoV-2-mRNA vaccination and a booster after six months. Anti-TNF-α-treated patients showed significantly lower antibody (Ab) levels and fas
Externí odkaz:
https://doaj.org/article/af0e7bd0d2944b3bb222d123ec80fe21
Autor:
Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Selma Tobudic, Helga Radner, Peter Mandl, Lisa Göschl, Maximilian Koblischke, Nikolaus Hommer, Angelika Wagner, Margareta Mayer, Lorenz Schubert, Lukas Hartl, Karin Kozbial, Philipp Hofer, Felix Kartnig, Thomas Hummel, Andreas Kerschbaumer, Thomas Deimel, Antonia Puchner, Venugopal Gudipati, Renate Thalhammer, Petra Munda, Keziban Uyanik-Ünal, Andreas Zuckermann, Gottfried Novacek, Thomas Reiberger, Erika Garner-Spitzer, Roman Reindl-Schwaighofer, Renate Kain, Stefan Winkler, Josef S. Smolen, Karin Stiasny, Gottfried F. Fischer, Thomas Perkmann, Helmuth Haslacher, Markus Zeitlinger, Ursula Wiedermann, Judith H. Aberle, Daniel Aletaha, Leonhard X. Heinz, Michael Bonelli
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Optimizing COVID-19 vaccination strategies for patients under immunosuppressive medication is of high importance. In this clinical trial including non-seroconverted immunosuppressed patients, a homologous mRNA booster vaccination resulted in higher s
Externí odkaz:
https://doaj.org/article/681a28347eb1429cb5190cc8fa0a5dd3
Autor:
Nina Worel, Katharina Grabmeier-Pfistershammer, Bernhard Kratzer, Martina Schlager, Andreas Tanzmann, Arno Rottal, Ulrike Körmöczi, Edit Porpaczy, Philipp B. Staber, Cathrin Skrabs, Harald Herkner, Venugopal Gudipati, Johannes B. Huppa, Benjamin Salzer, Manfred Lehner, Nora Saxenhuber, Eleonora Friedberg, Philipp Wohlfarth, Georg Hopfinger, Werner Rabitsch, Ingrid Simonitsch-Klupp, Ulrich Jäger, Winfried F. Pickl
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
BackgroundChimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. Despite this het
Externí odkaz:
https://doaj.org/article/b9b90c9752894772a6c70577e2f23cde
Autor:
Erika Garner-Spitzer, Angelika Wagner, Michael Kundi, Hannes Stockinger, Anna Ohradanova-Repic, Laura Gebetsberger, Anna-Margarita Schoetta, Venugopal Gudipati, Johannes B. Huppa, Renate Kunert, Patrick Mayrhofer, Thomas R. Kreil, Maria R. Farcet, Eva Hoeltl, Ursula Wiedermann
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
In a SARS-CoV-2 seroprevalence study conducted with 1,655 working adults in spring of 2020, 12 of the subjects presented with positive neutralization test (NT) titers (>1:10). They were here followed up for 1 year to assess their Ab persistence. We r
Externí odkaz:
https://doaj.org/article/b4ff2729839b47aca362fe1b6114797c
Autor:
Mark Smyth, Kseniya Khamina, Alexandra Popa, Venugopal Gudipati, Benedikt Agerer, Alexander Lercher, Lindsay Kosack, Lukas Endler, Hatoon Baazim, Csilla Viczenczova, Johannes B. Huppa, Andreas Bergthaler
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cytotoxic T lymphocytes (CTLs) represent key immune effectors of the host response against chronic viruses, due to their cytotoxic response to virus-infected cells. In response to this selection pressure, viruses may accumulate escape mutations that
Externí odkaz:
https://doaj.org/article/189e3d41775e41b897b0e95c658d10e2
Autor:
Elisabeth Lobner, Anna Wachernig, Venugopal Gudipati, Patrick Mayrhofer, Benjamin Salzer, Manfred Lehner, Johannes B. Huppa, Renate Kunert
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 8 (2020)
The transmembrane protein CD19 is exclusively expressed on normal and malignant B cells and therefore constitutes the target of approved CAR-T cell-based cancer immunotherapies. Current efforts to assess CAR-T cell functionality in a quantitative fas
Externí odkaz:
https://doaj.org/article/0f365f4fccb444509b2ae58a3233f0cf
Autor:
Anthea Wirges, Mario Bunse, Jara J. Joedicke, Eric Blanc, Venugopal Gudipati, Michael W. Moles, Hiroshi Shiku, Dieter Beule, Johannes B. Huppa, Uta E. Höpken, Armin Rehm
Publikováno v:
Molecular Therapy. 30:3358-3378
Chimeric antigen receptor (CAR) T cells have revolutionized treatment of B cell malignancies. However, enhancing the efficacy of engineered T cells without compromising their safety is warranted. The estrogen receptor-binding fragment-associated anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdf8f3cde4606133d57bf5b7f34934ef
https://doi.org/10.1016/j.ymthe.2022.07.009
https://doi.org/10.1016/j.ymthe.2022.07.009